Dr. Erickson has worked to obtain continuous federal, foundation, internal, and industry funding supporting his and his collaborators' research over the last 10 ten years of his career. He is the inventor or co-inventor on many patents focused on translational treatment development in neurodevelopmental disorders that are held at Cincinnati Children's Hospital Medical Center and at his previous employer the Indiana University School of Medicine. He is considered an international expert in the clinical treatment of fragile X syndrome and has similar expertise in fragile X-specific clinical trial development. Dr. Erickson is additionally an avid teacher of future generations of child psychiatrists has received several teaching awards for his work in physician education. He also enjoys mentoring junior faculty in the behavioral and developmental neuropsychiatry sub-field of child psychiatry.
Specifically in research, he and his colleagues have moved forward several repurposed molecules for study in fragile X syndrome and autism spectrum disorder including work with acamprosate, riluzole, ketamine, D cycloserine, and N acetyl cysteine among other repurposed molecules. He also is working now to move several novel molecules into autism and fragile X-specific study using proprietary compounds abandoned from initially intended use that may hold promise in the disorders which he and his colleagues study.
MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2003.
MS: Indiana University School of Medicine, Indianapolis, IN, 2008.
Residency and Fellowship: Indiana University School of Medicine, Indianapolis, IN, 2003-2008.
Certification: Child and Adolescent Psychiatry, 2009; Adult Psychiatry, 2008.
Fragile X syndrome; inpatient neurodevelopmental disorders acute crisis stabilization
Fragile X syndrome; autism spectrum disorders; neurodevelopmental disorders; molecular blood markers; quantitative measurement of pathophysiology in developmental disabilities; translational treatment development; psychiatric services for those with developmental disabilities and severe behavior
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Behavioral inflexibility in fragile X syndrome: Accounts from caregivers and self-advocates. Frontiers in Psychology. 2023; 14:1118652.
Neuropsychiatric feature-based subgrouping reveals neural sensory processing spectrum in female FMR1 premutation carriers: A pilot study. Frontiers in Integrative Neuroscience. 2023; 17:898215.
Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m). Frontiers in Psychiatry. 2023; 13:1079006.
Parallel learning and cognitive flexibility impairments between Fmr1 knockout mice and individuals with fragile X syndrome. Frontiers in Behavioral Neuroscience. 2023; 16:1074682.
Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome. Molecular Autism. 2022; 13:47.
Hemispheric Utilization of Alpha Oscillatory Dynamics as a Unique Biomarker of Neural Compensation in Females with Fragile X Syndrome. ACS Chemical Neuroscience. 2022; 13:3389-3402.
A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). Journal of Neurodevelopmental Disorders. 2022; 14:56.
Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. Journal of Neurodevelopmental Disorders. 2022; 14:52.
THALAMOCORTICAL DYSRHYTHMIA AS A UNIFYING MODEL OF NEUROPSYCHIATRIC AND NEUROSENSORY DYSFUNCTION IN FRAGILE X SYNDROME. Journal of the American Academy of Child and Adolescent Psychiatry. 2022; 61:s275-s276.